Breaking the Crosstalk of the Cellular Tumorigenic Network: Hypothesis for Addressing Resistances to Targeted Therapies in Advanced NSCLC

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Apr 14

PMID 28402937

Citations 5

Authors

Stefan Langhammer

Joachim Scheerer

Affiliations

Soon will be listed here.

Abstract

In the light of current treatment developments for non-small cell lung cancer (NSCLC), the idea of a plastic cellular tumorigenic network bound by key paracrine signaling pathways mediating resistances to targeted therapies is brought forward. Based on a review of available preclinical and clinical data in NSCLC combinational approaches to address drivers of this network with marketed drugs are discussed. Five criteria for selecting drug combination regimens aiming at its disruption and thereby overcoming resistances are postulated.

Citing Articles

Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts.

Gurgen D, Conrad T, Becker M, Sebens S, Rocken C, Hoffmann J Commun Biol. 2022; 5(1):59.

PMID: 35039644 PMC: 8763947. DOI: 10.1038/s42003-022-03016-5.

Cancer-Associated Fibroblasts Differentiated by Exosomes Isolated from Cancer Cells Promote Cancer Cell Invasion.

Kim K, Sohn Y, Lee R, Yoo H, Kang J, Choi N Int J Mol Sci. 2020; 21(21).

PMID: 33142759 PMC: 7662577. DOI: 10.3390/ijms21218153.

Interaction between CXCR4 and EGFR and downstream PI3K/AKT pathway in lung adenocarcinoma A549 cells and transplanted tumor in nude mice.

Wu J, Liu Y, Ma Y, Wang R, Ji X, Zhang Y Int J Clin Exp Pathol. 2020; 13(2):132-141.

PMID: 32211093 PMC: 7061788.

Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.

Yang Z, Tam K Int J Biol Sci. 2018; 14(2):204-216.

PMID: 29483838 PMC: 5821041. DOI: 10.7150/ijbs.22955.

Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway.

Shao J, Zheng G, Chen H, Liu J, Xu A, Chen F Oncotarget. 2017; 8(45):78351-78364.

PMID: 29108234 PMC: 5667967. DOI: 10.18632/oncotarget.18640.

References

Egeblad M, Nakasone E, Werb Z . Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 2010; 18(6):884-901. PMC: 2905377. DOI: 10.1016/j.devcel.2010.05.012. View

Garon E, Ciuleanu T, Arrieta O, Prabhash K, Syrigos K, Goksel T . Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014; 384(9944):665-73. DOI: 10.1016/S0140-6736(14)60845-X. View

Chan B, Hughes B . Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015; 4(1):36-54. PMC: 4367711. DOI: 10.3978/j.issn.2218-6751.2014.05.01. View

Minguet J, Smith K, Bramlage P . Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives. Int J Cancer. 2015; 138(11):2549-61. DOI: 10.1002/ijc.29915. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

Tomasetti C, Vogelstein B . Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015; 347(6217):78-81. PMC: 4446723. DOI: 10.1126/science.1260825. View

Hellmann M, Rizvi N, Goldman J, Gettinger S, Borghaei H, Brahmer J . Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2016; 18(1):31-41. PMC: 5476941. DOI: 10.1016/S1470-2045(16)30624-6. View

Han W, Lo H . Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett. 2012; 318(2):124-34. PMC: 3304012. DOI: 10.1016/j.canlet.2012.01.011. View

Janne P, Mann H, Ghiorghiu D . Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung.... Clin Lung Cancer. 2016; 17(2):e1-4. DOI: 10.1016/j.cllc.2015.12.010. View

10.

Hara M, Nagasaki T, Shiga K, Takeyama H . Suppression of Cancer-associated Fibroblasts and Endothelial Cells by Itraconazole in Bevacizumab-resistant Gastrointestinal Cancer. Anticancer Res. 2016; 36(1):169-77. View

11.

Gainor J, Shaw A, Sequist L, Fu X, Azzoli C, Piotrowska Z . EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016; 22(18):4585-93. PMC: 5026567. DOI: 10.1158/1078-0432.CCR-15-3101. View

12.

Phillips R, Mestas J, Gharaee-Kermani M, Burdick M, Sica A, Belperio J . Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of.... J Biol Chem. 2005; 280(23):22473-81. DOI: 10.1074/jbc.M500963200. View

13.

Cirri P, Chiarugi P . Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res. 2011; 1(4):482-97. PMC: 3186047. View

14.

Jordan C, Guzman M, Noble M . Cancer stem cells. N Engl J Med. 2006; 355(12):1253-61. DOI: 10.1056/NEJMra061808. View

15.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Orimo A, Gupta P, Sgroi D, Arenzana-Seisdedos F, Delaunay T, Naeem R . Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005; 121(3):335-48. DOI: 10.1016/j.cell.2005.02.034. View

18.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

19.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

20.

Jung M, Rho J, Kim Y, Jung J, Jin Y, Ko Y . Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene. 2012; 32(2):209-21. DOI: 10.1038/onc.2012.37. View